micro-community-banner
Profile Image
  • Saved
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

Source : https://www.sciencedirect.com/science/article/abs/pii/S1936878X22001437?via=ihub

The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition. The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab produced...



Conclusions: The combination of statin and evolocumab after a non–ST-segment elevation myocardial infarction produces favorable changes in coronary atherosclerosis consistent with stabilization and regression. This demonstrates a potential mechanism for the improved clinical outcomes observed achieving very low LDL-C levels following an...

Profile Image
  • Saved
Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039577/

Language: English | French Shyann Hang, BSc, a Julieta Lazarte, PhD, a, b, c and Robert A. Hegele, MD a, b, c, ∗ We evaluated whether low-density lipoprotein cholesterol (LDL-C)...



Relevance: We evaluated whether low-density lipoprotein cholesterol (LDL-C) levels in familial hypercholesterolemia patients on triple lipid-lowering therapy would remain below intensification threshold values after withdrawal of ezetimibe.

Profile Image
  • Saved
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective - PubMed

Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35467312/

doi: 10.1007/s10557-021-07276-x. Online ahead of print. 1 The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing, China. 2 School of Pharmacy, Hangzhou Medical College, Hangzhou, China....


Conclusion: Compared with ezetimibe statins, the combination of evolocumab statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China.

Profile Image
  • Saved
Approach to patients with elevated low-density lipoprotein cholesterol levels - PubMed

Approach to patients with elevated low-density lipoprotein cholesterol levels - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35487874/

Elevated low-density lipoprotein cholesterol (LDL-C) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and lowering LDL-C levels reduces the risk of ASCVD. In patients with elevated LDL-C levels it...


Conclusion: Specifically, we discuss evidence indicating that the sooner one initiates therapy the better and the greater the reduction in LDL-C the better. Additionally, the higher the LDL-C level and the higher the risk of ASCVD, the greater the benefits of treatment. Using these principles will help in making decisions regarding the...

Profile Image
  • Saved
The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art Review - PubMed

The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35483759/

The National Cardiovascular Data Registry is a group of registries maintained by the American College of Cardiology Foundation. These registries are used by a diverse constituency to improve the quality...


Relevance: The National Cardiovascular Data Registry is a group of registries maintained by the American College of Cardiology Foundation. These registries are used by a diverse constituency to improve the quality and outcomes of cardiovascular care, to assess the safety and effectiveness of new therapies, and for research.

Profile Image